Developmental Research Program

发展研究计划

• 批准号: 10683997
• 负责人: Maria Monica Gramatges
• 金额: $ 7.33万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-20 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10683997
• 关键词: Acute; Acute Lymphocytic Leukemia; Address; Adolescent; Advisory Committees; Area; Award; Child; Childhood Acute Lymphocytic Leukemia; Clinical; Clinical Research; Collaborations; Core Facility; Data; Development; Discipline; Disparity; Eligibility Determination; Ensure; Epidemiologist; Equity; Ethnic Origin; Faculty; Funding; Future; Genetic; Grant; Grant Review; Health Disparities Research; Human; Institution; Interdisciplinary Study; Investigation; Latino; Malignant Childhood Neoplasm; Mentorship; Mission; Molecular; Monitor; Outcome; Peer Review Grants; Physicians; Pilot Projects; Prediction of Response to Therapy; Recording of previous events; Records; Reporting; Research; Research Personnel; Research Project Grants; Scientist; Site; System; Translational Research; Treatment-related toxicity; United States National Institutes of Health; Work; cancer health disparity; cost; ethnic disparity; high reward; high risk; improved outcome; innovation; member; novel strategies; outcome disparities; phenotypic data; programs

DEVELOPMENTAL RESEARCH PROGRAM (DRP) SUMMARY/ABSTRACT The objective of the Developmental Research Program (DRP) of this SPORE planning study is to support the development and successful completion of innovative, high-risk/high-reward pilot projects that aim to understand or reduce outcome ethnicity-based disparities in childhood acute lymphoblastic leukemia (ALL). This program will be co-led by Dr. Maria Monica Gramatges, a physician scientist, and Dr. Philip Lupo, a molecular epidemiologist. Drs. Gramatges and Lupo each have strong track records in translational research investigating genetic and molecular predictors of treatment-related toxicities in childhood cancer. Their complementary disciplines and history of collaboration evidence a strong commitment of the DRP to supporting multidisciplinary research. DRP-supported projects may be clinical or translational, but must address ethnic disparities in ALL treatment-related toxicities (acute or late onset). Eligibility to apply for a DRP Pilot Grant will extend to any faculty member of an institution participating in this application. Proposals will be scored using the NIH 9 point system, and selection for funding will be jointly determined by the DRP Committee. Membership to the DRP Committee will be distributed equally across all participating sites to ensure equity and transparency in award distribution, and will include faculty with expertise in clinical and translational research and who have a strong track record of participation in grant peer review. Criteria for funding will be work with strong scientific merit that is perceived as high-risk/high-impact in the above listed areas of concentration. Proposals representing collaborations between participating institutions will also be prioritized, as will proposals from junior faculty and new investigators (those with no prior independent federal funding) and those considered likely to result in future independent funding. All Pilot Grants will be awarded for one year, with an opportunity for a one-time, one-year renewal at the end of the first year. In addition to grant review and selection, the DRP Committee will be responsible for monitoring and oversight of funded projects via regular review of progress and final reports. The DRP's core mission is to provide grant awardees with 1) funding support, 2) access to core facilities, and 3) mentorship during the award period. A total of $75,000 will be budgeted to support funding of three Pilot Awards in Year 1 at $25,000 per award, and $90,000 per year in each subsequent year to support funding two Pilot Awards per year plus two renewals at $20,000 per renewal. All Pilot Grant PI's will be provided with access to the designated Cores with no associated cost, and will be required to use at least one Core. The DRP Committee will assign each funded project an Advisory Committee with relevant expertise, who will provide mentorship and guidance that is specific to each project. A key role of the Advisory Committee, together with the DRP Committee, will be to facilitate the transition/development of Pilot Grant data to work that is independently funded, with potential inclusion in a future P50 application.

发展研究计划（DRP）摘要/摘要 该孢子计划研究的发展研究计划（DRP）的目的是支持 开发和成功完成创新，高风险/高级试点项目，旨在 了解或减少儿童急性淋巴细胞白血病（ALL）的基于民族的差异。 该计划将由医师科学家Maria Monica Gramatges博士和Philip Lupo博士共同领导 分子流行病学家。博士。抓取和卢波在翻译研究中都有很强的记录 研究儿童癌症治疗相关毒性的遗传和分子预测因子。他们的 互补的学科和协作历史证据证明了DRP对支持的坚定承诺 多学科研究。 DRP支持的项目可能是临床或翻译的，但必须解决种族 所有与治疗有关的毒性（急性或晚期发作）的差异。申请DRP飞行员赠款的资格将 扩展到参加此申请的机构的任何教职员工。建议将使用 NIH 9点系统和资金选择将由DRP委员会共同确定。 DRP委员会的会员资格将在所有参与站点中平均分配，以确保公平和 奖励分配的透明度，并将包括具有临床和转化研究专业知识的教师 谁在参与Grant Peer Review的参与记录很强。资金标准将与 在上述集中度的领域中，强大的科学价值被认为是高风险/高影响力。 代表参与机构之间合作的建议也将优先考虑 初级教师和新调查员（没有以前没有独立联邦资金的调查员）的提案， 被认为可能导致未来的独立资金。所有飞行员赠款将获得一年的授予 在第一年末，一次续签了一年的机会。除了授予审查和 选择，DRP委员会将负责通过常规监视和监督资助的项目 审查进度和最终报告。 DRP的核心任务是为赠款获奖者提供1）资金 支持，2）访问核心设施，以及3）奖励期间的指导。总共75,000美元将是 预算以每年25,000美元的奖金和每年90,000美元的资金在第一年获得三项试点奖的资金 随后的每一年，每年为两个试点奖提供资金，加上两个续签，每次续签20,000美元。 所有飞行员赠款Pi都将提供对指定核心的访问，没有相关费用，并且将是 需要至少使用一个核心。 DRP委员会将分配每个资助的项目一个咨询委员会 具有相关的专业知识，谁将提供每个项目的指导和指导。一个关键角色 咨询委员会与DRP委员会一起将促进 试点授予的数据是独立资助的工作，并可能包含在未来的P50应用程序中。